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Sequence Specificity, Reactivity,
and Antitumor Activity of DNA-Alkylating
Pyrrole-Imidazole Diamides
and thereby create a tailor-made antitumor agent. The
study of DNA minor groove binders has emerged as a
methodology for the development of novel antitumor
agents with sequence recognition ability. On the basis
of earlier work on the concept of minor groove sequence
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Tokyo Medical and Dental University information readout [3–8], Dervan and colleagues have
developed minor-groove binding hairpin polyamides2-3-10 Surugadai
Kanda, Chiyoda-Ku, Tokyo 101-0062 containing N-methyl pyrrole (Py)-N-methyl imidazole
(Im) that uniquely recognize each of the four Watson-2 Second Department of Internal Medicine
Nihon University School of Medicine Crick base pairs [9–15]. A pairing of Im opposite Py
targets a G-C base pair, while Py/Im targets a C-G base30-1 Ooyaguchi-kami
Itabashi-Ku, Tokyo 173-8610 pair. Py/Py degenerately targets T-A and A-T base pairs
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Cancer Chemotherapy Center Duocarmycin A (Duo) [19–21] is an exceedingly potent
antitumor antibiotic isolated from Streptomyces sp. thatJapanese Foundation for Cancer Research
1-37-1 Kami-Ikebukuro selectively alkylates N3 of adenine (A) at the 3 end of
consecutive A·T base pairs in DNA [22]. Several yearsToshima-Ku, Tokyo 170-8455
Japan ago, we found that the addition of distamycin A (Dist)
causes efficient alkylation at the G residues in GC-rich
sequences [23] through a cooperative heterodimer for-
mation between Duo and Dist in the minor groove. ThisSummary
suggests that Dist recognizes the complementary
strand according to a similar binary code of Py-Im poly-Three conjugates of imidazole (Im)-pyrrole (Py) dia-
amides. We therefore believed that Py-Im polyamidesmide and a DNA-alkylating moiety derived from the
could be used as recognition components to deliverantibiotic duocarmycin A were synthesized, and their
alkylating agents to a target sequence. Thus, we pre-sequence specificity, reactivity, and antitumor activity
pared the hybrid molecules constructed from segmentcomparatively examined. Sequencing gel analysis in-
A of Duo and Py-Im polyamides [24, 25]. It was showndicated that ImPyDu (1) alkylates DNA at the 3 end
that these molecules specifically alkylate at predeter-of AT-rich sequences at micromolar concentration.
mined sequences within a 450 bp DNA fragment [25].ImPyDu86 (2) reacts with DNA at AT-rich sites together
Lown and colleagues have found that insertion of awith dialkylation sites at micromolar concentration.
trans-vinyl linker (L) between the Py and CPI groupsImPyLDu86 (3) efficiently alkylates dialkylation sites at
greatly enhanced the alkylating activity, as well as thenanomolar concentration. Average values of log IC50
cytotoxicity [26]. Based on this observation, we synthe-against a 39 cancer cell line panel of 1–3 were 4.59,
sized Py-Im diamide CPI conjugates with a vinyl linker,5.95, and8.25, respectively. The differential growth
ImPyLDu86 (3), and demonstrated that 3 efficientlyinhibition pattern of 1–3 varied with relatively low cor-
causes double alkylation of DNA at the 5-PyG(A/T)CPu-relation coefficients. Array-based gene expression
3/5-PyG(A/T)CPu-3 sequence through a highly coop-monitoring was performed for 3 in a human lung can-
erative homodimer formation [27]. We found that thecer cell line. Substantial downregulation of expression
efficiency of alkylation by 3, which is the amount of DNAwas seen for genes involved in DNA damage response,
alkylation divided by the amount of the agent, was 69%,transcription, and signal transduction.
thus confirming the unusually high efficiency of dialky-
lation.
Introduction In developing an efficient sequence-specific alkylat-
ing agent, we found that the choice of alkylating moiety
DNA-alkylating agents have long been of interest for and linker region are very important. We describe here a
their biological properties. They constitute a major class comparative study of DNA sequence-specific alkylation
of such antitumor drugs as nitrosoureas, mitomycin C, and antitumor activity of three different alkylating ImPy
cisplatin, and nitrogen mustards, and they are routinely diamide conjugates 1–3 utilizing high-resolution dena-
used in hospitals. Many alkylating antitumor agents are, turing gel electrophoresis and a panel of 39 human can-
in fact, practically nonselective and cannot distinguish cer cell lines. To gain insight into the origin of the intense
between cancer cells and normal cells; as a result, they antitumor activity of ImPyLDu86 (3) expression level, a
exhibit severe toxicity to normal tissues. Recently, it has gene chip analysis was also performed.
become evident that DNA sequence specificity is an
important component contributing to the cytotoxic po- Results and Discussion
tency of several antitumor agents [1, 2]. Therefore, the
question arises whether one can tailor the binding pref- Synthesis and Solvolytic Stability of ImPy
erence of DNA binding agents to particular sequences Diamide Conjugates 1–3
We synthesized ImPy diamide conjugates 1 and 2 as
shown in Figure 1. Carboxylic acid 4 was activated with*Correspondence: sugiyama.chem@tmd.ac.jp
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Figure 1. Structures and Synthesis of Conju-
gates 1, 2, and 3
CDI to 5, which was coupled with segment A of Duo or TAAA-3 (site 2), 5-ACAA-3 (site 3), 5-ATAA-3 (site 7)
(lanes 1–4). These results clearly indicate that 1 alkylatesDU-86 to provide 1 and 2, respectively. Segment A of
Duo and DU-86 was prepared according to the reported DNA in a simple monomeric binding mode and that the
ImPy diamide moiety of 1 does not effectively recognizeprocedures [28]. Compound 3 was prepared by pre-
viously reported procedures [27]. The conjugates 1–3 G-C base pairs except for the alkylation at site 3, which
could be explained by recognition of Im in the mono-were purified by reverse phase HPLC and subjected to
DNA alkylation and cytotoxicity experiments. The solvo- meric binding mode reported by Dervan et al. [30]. Inter-
estingly, alkylation by 2 occurred at specific sequenceslytic stability of 1–3 was examined in 5 mM sodium
phosphate buffer (pH 7.0) containing 20% DMF at 37C in close proximity, such as 5-CGACA-3 (site 4)/5-
TGTCG-3 (site 10), 5-CGACG-3 (site 5)/5-CGTCG-3by monitoring the disappearance of 1–3 by HPLC. It was
observed that the half-lives of 1–3 are 3, 53, and 53 hr, (site 9), 5-TGACG-3 (site 6)/5-CGTCA-3 (site 8), to-
gether with AT-rich sites as observed in the case of 1respectively, indicating that the extension of conjuga-
tion greatly stabilizes the solvolytic stability. Enhanced (lanes 5–8). These results clearly indicate that substitu-
tion of the alkylating moiety with segment A of the DU-solvolytic stability of 2 and 3 relative to 1 is consistent
with the previous observation of Duo compared with 86 unit increased the planarity of the molecule, which
allows double alkylation of DNA at 5-PyG(A/T)CPu-3/duocarmycin SA [29].
5-PyG(A/T)CPu-3 through cooperative homodimer for-
mation. As previously reported, 3, which possesses a
Evaluation of DNA Alkylation by 1–3 Using vinyl linker relative to 2, alkylated the 5-PyG(A/T)CPu-
450 bp DNA Fragments 3 (sites 4–6 and 8–10) at a concentration of 10010 nM
Sequence-selective alkylation by compounds 1–3 was of 3 (lanes 9–12). The significantly improved reactivity
investigated on 5 Texas red-labeled 450 bp DNA frag- of 3 could be attributed to highly cooperative homodimer
ments using an automated DNA sequencer, as pre- formation in the DNA minor groove. These results con-
viously described [24, 25, 27]. Alkylation was carried out firmed that incorporation of a vinyl linker paired with Im
at 23C for 24 hr and quenched by the addition of calf substantially improves the reactivity of ImPy diamide
thymus DNA. Samples were heated at 94C under neu- Du86 conjugates. Therefore, these results also suggest
tral conditions for 20 min. The sites of alkylation were that 3 effectively alkylates DNA according to the Py-Im
visualized by thermal cleavage of the DNA strand at pairing rule, and exhibits a new mode of recognition in
the alkylated sites. Under these heating conditions, all which the Im-vinyl linker (L) pair targets G-C base pairs.
purine N3-alkylated sites in the DNA produced cleavage
bands almost quantitatively on the gel. Subsequent hot
piperidine treatment (0.1 M, 90C, 20 min) did not further Evaluation of 50% Growth Inhibition by 1–3
against a Panel of 39 Cancer Cell Linesenhance the cleavage bands, indicating that the neutral
heating conditions used (94C, 20 min) were sufficient The Cancer Chemotherapy Center in Japan has estab-
lished a new human cancer cell line panel, which con-to cleave all the DNA-alkylated sites. Sequencing analy-
sis of the alkylated DNA fragments after heat treatment sists of 39 human cancer cell lines [31, 32], coupled with
a drug sensitivity database that is similar to the Nationalis shown in Figure 2.
Alkylation of 10 nM of the DNA fragment by 1 or 2 Cancer Institute cancer cell line panel [33–35]. New com-
pounds can be compared with standard drugs for thewas observed at 100 M concentration of the agent.
Several alkylations by 1 occurred predominantly at the 50% cell growth inhibition (IC50) mean graphs using
COMPARE analysis and examined to see if new com-3 end A of AT-rich sequences, 5-AAAA-3 (site 1), 5-
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Figure 2. Sequence Specific DNA-Alkylation by Conjugates 1, 2, and 3
Thermally induced strand cleavage of 5 Texas red-labeled 450 bp DNA fragments by conjugates 1–3. Results using 5 end-labeled top strand
(pUC 18 F7801229) (A) and 5 end-labeled bottom strand (pUC 18 R14591908) (B) DNA fragments are shown. These two DNA fragments
are complementary. Lanes 1–4: 500, 200, 100, and 50 M of 1; lanes 5–8: 500, 200, 100, and 50 M of 2; lanes 9–12: 100, 50, 25, and 10 nM
of 3; lane 13: DNA control. Sequences containing alkylation sites are represented (C). Arrows indicate the site of alkylation by 1–3. Alkylated
bases are shown in red.
pounds having unique or similar mechanisms are clus- (5.62 nM), which can be attributed to dramatic improve-
ment of DNA alkylation activity by the insertion of atered together. In general, the panel patterns of drugs
possessing a common mechanism resembled one an- vinyl linker between the minor groove binder and the
alkylating moiety. The COMPARE analysis of the meanother (r  0.75).
Using this human cancer cell line panel, we investi- graphs showed that the ImPy diamide conjugates 1–3
did not correlate well with each other (r  0.55–0.68)gated the IC50 profile of the ImPy diamide CPI conjugates
1–3, as shown in Figure 3. The mean log IC50 of 1 was despite having a common DNA-alkylating mechanism.
It is generally accepted in a COMPARE analysis that4.59 (25.7M), which is comparable with the presently
used anticancer drug 5-fluorouracil. In contrast, the higher correlation coefficients (r  0.75) are observed
for anticancer agents possessing the same reactionmean log IC50 of 2 was increased to 5.95 (1.12 M)
because of its high stability in the cell. Interestingly, the mechanism. For example, the correlation coefficient be-
tween doxorubicin and daunorubicin (DNA intercalater)mean log IC50 of 3 was significantly increased to 8.25
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Figure 4. The Results of Compare Analysis of 1–3 with Those of
200 Standard Antitumor Agents
The top five compounds were ordered according to the correlation
coefficient. Doxorubicin, Epirubicin (DNA intercalater) were drawn
in blue. SN-38, Camptothecin-1, SK&F 104864 (Topo I inhibitor) were
drawn in red. Mitoxantrone, ICRF-193 (Topo II inhibitor) were drawn
in green. Taxol, Vincristine (tubulin inhibitor) were drawn in purple.
Neocarzinostatin (DNA damage) was drawn in black.
is 0.93 [36]. The value for ecteinascidin Et 743 and
phthalascidin Pt 650 (guanine N2 alkylation) is 0.90 [37].
Therefore, the correlation coefficients between 1, 2, and
3 (purine N3 alkylation), which are in the range 0.55–0.68,
are remarkably low. These results suggest that the dif-
ference in sequence specificity of 1–3 may reflect the
pattern’s difference in the mean graphs and relatively
low correlation coefficient with one another. Sequence
specificity of alkylating Py-Im polyamide can be changed
in a predictable manner; therefore, a sequence-specific
alkylating agent targeting a predetermined specific se-
quence in cancer cells will be a promising approach for
the development of tailor-made antitumor drugs.
By comparing with the result of the screening panel
of existing anticancer drugs, it became clear that an
interesting tendency existed as shown in Figure 4. The
chemical compound that showed the highest correlation
coefficient of the screening panel of 1 and 2 was the
DNA intercalating agent, doxorubicin. For both 3 and
2, mitoxantrone, which is a Topoisomerase II inhibitor,
came second. The first resembled compound for 3
was found to be Topoisomerase I inhibitor SN38, which
was the third for 2. The third resembled compound for
3 was camptothecan, which was the fourth for 2. These
results indicate that resemblances of the screening
panel roughly corresponds to the DNA binding modes
with which 1 and 3 alkylate DNA as the monomer and
dimer, respectively, and 2 possesses both properties.
Analysis of Gene Expression Profiles by
ImPyLDu86 (3) Using a Gene Chip
Since conjugate 3 shows intense cytotoxicity againstFigure 3. The Mean Graphs of 50% Growth Inhibition against a
human cancer cell lines, array-based gene expressionsPanel of 39 Human Cancer Cell Lines
were performed using HLC-2. It was found that incuba-The log IC50 for each cell line is indicated. Columns extending to
tion of 1 nM of 3 induced downregulation of 123 genesthe right, more sensitive to agents; columns extending to the left,
less sensitive to agents. One unit represents one logarithm dif- (2-fold) and 85 genes (4-fold) among 2069 genes, as
ference. shown in Figure 5. It is important to note that only 1 nM
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Figure 5. 87 Columns Comparing Sets of Downregulated (85 genes) and Upregulated (2 genes) Genes Using ImPyLDu86 (3) in the HLC-2
Lung Cancer Cell
The transcription amounts of m-RNA in control cells are drawn in the blue column, and those in drug-treated cells are drawn in the red column.
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Table 1. Gene Expression Changes Caused by ImPyLDu86 (3)
Accession No. Treated Cell Control Cell Fold Change Gene Definition
Downregulated Genes (85/2069 Genes)
M29870 21 245 11.3 Ras-related C3 botulinum toxin
substrate (Rac)
8 134 17.4 Ras-like protein Tc4
L24564 14 110 7.9 Rad
D78132 11 117 10.3 Ras-related GTP-binding protein
D87116 22 95 4.3 MAP kinase kinase
X56681 69 303 4.4 junD
M84711 112 579 5.1 v-fos transformation effector protein
M25753 7 109 14.7 Cyclin B
14 157 11.0 Cyclin protein
U37022 20 142 6.9 Cyclin-dependent kinase 4 (CDK4)
U33760 22 89 4.0 Cyclin A/CDK2-associated p19
23 184 8.1 -tubulin
J00314 13 97 7.5 -tubulin
U47634 53 406 7.7 -tubulin class III isotype (-3)
X00734 20 267 13.5 -tubulin 5-
Upregulated Genes (2/2069 Genes )
M27830 245 37 6.6 28S ribosomal RNA
U19599 103 31 3.3 BAX delta
of 3 is needed to exert such significant effects on the the antitumor activities of 1–3 can be explained by the
combination of alkylating activities together with theirgene expression after 1 hr.
The results of regulated genes summarized in Table solvolytic stabilities. The differential growth inhibition
patterns of 1–3 varied, with relatively low correlation1 show that 3 affects many sets of gene expression,
which is related to DNA-alkylating damage response, coefficients among the responding cell lines, implying
that sequence specificity might affect antitumor activ-transcription, and signal transduction. Especially dra-
matic changes were observed in subsets of genes in- ity toward certain cancer cell lines. Array-based gene
expression monitoring was performed for 3 in the hu-volved in Ras, cyclin B, and tubulin . The level of gene
expressions were observed to be less than 1/10 relative man lung cancer cell line HLC-2. Characteristic changes
were observed in subsets of genes involved in DNAto that of the control cells. A concentration of only 1 nM
of 3 for 1 hr seriously damaged DNA in the cancer cell. damage response, transcription, and signal transduc-
tion. To the best of our knowledge, this is the firstThe inhibition of Ras gene expression results in the inhi-
bition of MAPKK, jun, and fos in the downstream of gene gene array analysis of alkylating Py-Im polyamide, and
sets a minimum baseline for evaluation. The presentexpression. The high inhibition of these gene transcrip-
tions might cause inhibition of cell growth and cell divi- results suggest the intriguing possibility that the effec-
tive DNA-alkylating agent recognized for longer basesion by DNA alkylation. In contrast, only two upregulated
genes ( 2-fold), human BAX delta and 28S ribosomal pair sequences may provide a promising approach for
developing new types of biological agents to controlRNA, were observed in the HLC-2 cell. A possible expla-
nation for the characteristic upregulation is that 3 may gene expression [38, 39]. This paves the way for a
“tailor-made antitumor agent” by sequence-specificspecifically activate transcription for apoptosis in this
cancer cell. alkylating Py-Im polyamides.
Experimental ProceduresSignificance
Chemicals
To date, various types of minor groove alkylating Reagents and solvents were purchased from standard suppliers
agents have been synthesized, but the relationship and used without further purification. Abbreviations of some re-
agents: CDI, 1,1-carbonyldiimidazole; DMF, N,N-dimethylform-between sequence specificity and antitumor activity
amide. Reactions were monitored by thin-layer chromatographyis not well understood. In this study, three different
(TLC) using 0.25 mm silica gel 60 plates impregnated with 254 nmconjugates of ImPy diamide and an alkylating moiety
fluorescent indicator (from Merck). Plates were visualized by UVderived from the antibiotic Duo were comparatively
illumination. NMR spectra were recorded with a JEOL JNM-A 500
examined. Sequence specificity and reactivity of ImPy nuclear magnetic resonance spectrometer, and tetramethylsilane
diamide conjugates 1–3 dramatically depend on the was used as the internal standard. Proton NMR spectra were re-
corded in parts per million (ppm) downfield relative to tetramethylsi-structure of the alkylating agent and the linker region
lane. The following abbreviations apply to spin multiplicity: s, singlet;between the alkylating moiety and the recognition
d, doublet; m, multiplet; and br, broad. Electrospray ionization massmoiety. Antitumor activity of 1–3 was examined using
spectra (ESMS) were produced on a PE SCIEX API 165 mass spec-a 39 human cancer cell line panel coupled with a drug
trometer. Polyacrylamide gel electrophoresis was performed on a
sensitivity database. Average logs IC50 against the 39 HITACHI 5500-S DNA Sequencer. Ex Taq DNA polymerase and Su-
cancer cell line panel of 1–3 were 4.59, 5.95, and prec-02 purification cartridges were purchased from Takara Co.,
the Thermo Sequenase core sequencing kit and loading dye (di-8.25, respectively. The results clearly indicate that
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methylformamide with fuchsin red) from Amersham Co. Ltd, 5Texas The resulting cDNA was purified by phenol/chloroform extraction
with Phase Lock Gel (5 to 3, Inc. Boulder, CO), and concentratedred-modified DNA oligomer (18-mer) from Kurabo Co. Ltd and 50%
Long Ranger gel solution from FMC Bioproducts. The following by ethanol precipitation. Synthetic double-stranded cDNA transcrip-
tion into biotin-labeled cRNA was done in vitro with a MEGAscriptdrugs were synthesized by the reported procedures [24, 25]. Im-
PyDu (1): 1H NMR (500 MHz, CDCl3)  8.68 (s, 1H; NH), 7.68 (brs, T7 kit (Ambion, Austin, Texas). Biotin-labeled cRNA was then iso-
lated with an RNeasy Mini Kit (Qiagen, Tokyo, Japan) and precipi-1H; NH), 7.33 (s, 1H; CH), 7.31 (d, J  1.5 Hz, 1H; CH), 6.51 (d, J 
1.5 Hz, 1H; CH), 6.43 (s, 1H; CH), 6.10 (s, 1H; NH), 4.19 (dd, J  5 tated with ethanol. The cRNA was fragmented to 50–200 nucleotide
pieces as described by Wodicka et al. [42]. After fragmentation, 5Hz, 11 Hz, 1H; NCHH ), 4.01 (d, J  11 Hz, 1H; NCHH), 3.98 (s, 3H;
NCH3), 3.78 (s, 3H; NCH3), 3.67 (s, 3H; OCH3), 2.86 (m, 1H; CH), 2.22 g of cRNA was injected into a Human Cancer G110 Array probe
array cartridge (Affymetrix), which contains probe sets for 2069(m, 1H; CHH ), 2.10 (s, 3H; COCH3), 1.60 (s, 3H; CH3), 1.24 (m, 1H;
CHH); ESMS m/z calcd for C27H28N7O7 [M	 	 H] 562.2, found 562.1. genes including ca. 1700 human cancer related genes for hybridiza-
tion. The G110 array contains oligonucleotides representing tran-ImPyDu86 (2): 1H NMR (500 MHz, [D6]DMSO)  12.36 (s, 1H; NH),
10.18 (s, 1H; NH), 9.98 (s, 1H; NH), 7.46 (d, J  1.5 Hz, 1H; CH), 7.42 scripts of metabolic enzymes, growth factors and receptors, kinases
and phosphatases, nuclear receptors, transcription factors, DNA(s, 1H; CH), 6.86 (d, J  1.5 Hz, 1H; CH), 6.16 (s, 1H; CH), 4.24 (dd,
J  5 Hz, 11 Hz, 1H; NCHH ), 4.08 (d, J  11 Hz, 1H; NCHH), 3.94 damage repair genes, apoptosis genes, stress response genes,
membrane proteins, and cell cycle regulators. Probe arrays were(s, 3H; NCH3), 3.73 (s, 6H; NCH3 and OCH3), 3.41 (m, 1H; CH), 2.47
(s, 3H; CH3), 2.17 (m, 1H; CHH ), 2.02 (s, 3H; COCH3), 1.40 (m, 1H; treated with biotinylated anti-streptavidin goat antibody (Vector
Laboratories, Burlingame, CA) and stained with streptavidin phy-CHH); ESMS m/z calcd for C27H28N7O6 [M	 	 H] 546.2, found 546.1.
coerythrin (Molecular Probes, Eugene, OR). Probe arrays were
scanned twice with a GeneChip scanner at a resolution of 3 m. ThePreparation of 5 Texas Red-Modified 450 bp DNA Fragments
intensity for each feature of the array was captured with AffymetrixThe 5 Texas red-modified 450 bp DNA fragments pUC18 F780*-
GeneChip Expression Analysis Software according to standard Affy-1229 and pUC18 R1459*-1908 (these two DNA fragments are com-
metrix procedures, and the gene expression data were analyzedplementary) were prepared by PCR using 5 Texas red-modified 20-
with Microsoft Excel. Expression values of transcription in differentmer primers: 5-AGAATCAGGGGATAACGCAG-3 (pUC18 forward,
groups were normalized by adjusting GAPDH expression as 5000 to780–799) and 5-TTACCAGTGGCTGCTGCCAG-3 (pUC18 reverse,
the same value. The final values for each transcription as increments1459–1478). Fragments were purified by filtration using Suprec-02,
were the mean of duplicate values for treated HLC-2 cells minusand their concentrations were determined by UV absorption. The
the average values for nontreated HLC-2 cells. All quantitative dataasterisk indicates Texas red modification and the nucleotide num-
were processed using the Affymetrix GeneChip software. 4-foldbering starts with the replication site.
downregulated expression and 2-fold upregulated expression were
shown in Figure 5.High-Resolution Gel Electrophoresis
The 5 Texas red-labeled DNA fragments (10 nM) were alkylated by
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